期刊
ACS INFECTIOUS DISEASES
卷 4, 期 8, 页码 1264-1274出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.8b00113
关键词
Medicines for Malaria Venture; Apicomplexa; antibiotics; chronic infection; bradyzoite; latency
资金
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U19AI109725]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI109725] Funding Source: NIH RePORTER
Toxoplasma gondii is a common zoonotic infection of humans, and estimates indicate that 12 billion people are chronically infected. Although largely asymptomatic, chronic infection poses risk of serious disease due to reactivation should immunity decline. Current therapies for toxoplasmosis only control acute infection caused by actively proliferating tachyzoites but do not eradicate the chronic tissue cyst stages. As well, there are considerable adverse side effects of the most commonly used therapy of combined sulfadiazine and pyrimethamine. Targeting the folate pathway is also an effective treatment for malaria, caused by the related parasites Plasmodium spp., suggesting common agents might be used to treat both infections. Here, we evaluated currently approved and newly emerging medicines for malaria to determine if such compounds might also prove useful for treating toxoplasmosis. Surprisingly, the majority of antimalarial compounds being used currently or in development for treatment of malaria were only modestly effective at inhibiting in vitro growth of T. gondii tachyzoites. These findings suggest that many essential processes in P. falciparum that are targeted by antimalarial compounds are either divergent or nonessential in T. gondii, thus limiting options for repurposing of current antimalarial medicines for toxoplasmosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据